The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid, MD, MS, FACP, MRCP, FRCP, Texas Tech University Health Sciences Center, Lubbock, TX, discusses a real-world analysis from CIBMTR evaluating infections in patients with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel) therapy. Dr Bilal Abid reports that infection-related mortality was low, but infections within the first 100 days impacted overall survival. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
